Search clinical trials for: Ceritinib (LDK378)

Total 501 results

Puma Biotechnology, Inc.

Completed

Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)

Breast Cancer

United States
Massachusetts General Hospital
Puma Biotechnology, Inc.; Celcuity, Inc.

Withdrawn

Fulvestrant + Neratinib In Breast Cancer (HER2-Signal)

Metastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer | Stage IV (Metastatic) Breast Cancer

United States
AstraZeneca

Completed

A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone (IMPRESS)

Non-Small Cell Lung Cancer

Italy, Spain, France, Korea, Republic of, Hungary, Japan, China, Taiwan, Hong Kong, Germany, Russian Federation
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer

Squamous Cell Carcinoma of the Skin | Recurrent Skin Cancer

United States
AstraZeneca

Completed

Phase II Iressa + Irradiation Followed by Chemo in NSCLC

Non-Small Cell Lung Cancer

France
AstraZeneca

Completed

ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer

Non Small Cell Lung Carcinoma

Australia
Tang-Du Hospital

Unknown

Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma

Lung Neoplasms

China
AstraZeneca

Terminated

Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Taiwan
Eli Lilly and Company

Completed

A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non Small Cell Lung

Taiwan, Japan, Korea, Republic of, China
National Institute for Medical Research, Tanzania
Universiteit Antwerpen

Unknown

Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania (InSMART-school)

Anemia | Malaria,Falciparum

Tanzania
AstraZeneca

Completed

First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia (IPASS)

Non-Small Cell Lung Cancer

Philippines, China, Malaysia, Japan, Hong Kong, Taiwan, Thailand, Indonesia, Singapore
Puma Biotechnology, Inc.

Completed

Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors

Neoplasms | Malignant Carcinoma

United States, France
Eli Lilly and Company

Completed

Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers

Non-small Cell Lung Cancer

China, Korea, Republic of, Taiwan
Samsung Medical Center

Unknown

Pemetrexed (ALIMTA) and Gefitinib (IRESSA®) in Never-Smoker and Adenocarcinoma Patients With Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

Non-small Cell Lung Cancer

Korea, Republic of
Roswell Park Cancer Institute
Novartis

Completed

Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer

Advanced Malignant Solid Neoplasm | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | ALK Positive

United States
AstraZeneca
Quintiles, Inc.

Completed

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)

United States
Gachon University Gil Medical Center

Completed

Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients

Previous Treated Metastatic Non-small Cell Lung Cancer

Korea, Republic of
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca

Completed

Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas

Gastric Cancer | Esophageal Cancer

United States, Puerto Rico
Yazd Research & Clinical Center for Infertility

Completed

Clomiphene Citrate (CC)/Gonadotropin/Gonadotropin Releasing Hormone (GnRH) Antagonist Versus Gonadotropin/GnRH Agonist

Ovarian Stimulation

Iran, Islamic Republic of
Eli Lilly and Company

Completed

A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer

Non Small Cell Lung Cancer

Taiwan, Korea, Republic of, Singapore, Thailand, Hong Kong
IRCCS Azienda Ospedaliera Universitaria San Martino...

Unknown

GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial

Non Small Cell Lung Cancer

Italy
Sun Yat-sen University
Shenzhen People's Hospital; Sixth Affiliated Hospital, Sun Yat-sen University; Dongguan People's Hospital and other collaborators

Not yet recruiting

Clinical Trial of Neoadjuvant Targeted Treatment to NSCLC Patients

2-year Disease-Free Survival

China
AIO-Studien-gGmbH
AstraZeneca

Terminated

Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB (NeoIntercal)

NSCLC | Non-squamous Non-small Cell Lung Cancer Stage II | Non-squamous Non-small Cell Lung Cancer Stage IIIA | Non-squamous Non-small Cell Lung Cancer Stage IIIB | Activating EGFR Mutation

Germany
Fudan University

Unknown

Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients

Non-small Cell Lung Cancer | Toxicity

China
Guangdong Association of Clinical Trials
Peking University First Hospital; Zhejiang Cancer Hospital; Peking University... and other collaborators

Unknown

Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation (ADJUVANT)

Non-small Cell Lung Cancer

China
Memorial Sloan Kettering Cancer Center
Puma Biotechnology, Inc.

Active, not recruiting

Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer

Breast Cancer

United States
AstraZeneca

Completed

IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in Locally Advanced Pancreatic Cancer

Pancreatic Cancer

Spain
Merck KGaA, Darmstadt, Germany

Completed

Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)

Non-small Cell Lung Cancer

Spain, Taiwan, Korea, Republic of, Singapore, China, Malaysia, Italy
Puma Biotechnology, Inc.

Completed

Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer (NEFERTT)

Breast Cancer

Spain, China, United States, Australia, Hong Kong, Malaysia, Korea, Republic of, Singapore, Belgium, Japan, India, France, Hungary, Romania, Italy, Bulgaria, Germany, Serbia, United Kingdom, South Africa, Canada, Israel, Taiwan, Switz... and more
Novartis Pharmaceuticals

Recruiting

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

Advanced Solid Tumors Which Are cMET-dependent

Germany, Korea, Republic of, Belgium, Italy, Singapore, United States, Denmark, Spain, France, Canada
Samsung Medical Center

Completed

Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

Stomach Neoplasms

Korea, Republic of
LycoRed Ltd.

Completed

Effect of Tomato Extracted Lycopene on Postprandial Oxidation and inﬂammation in Healthy Weight Men and Women

Postprandial Oxidation and inﬂammation

Israel
AstraZeneca

Completed

Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT

Bladder Cancer

Germany
National Cancer Center, Korea
AstraZeneca

Unknown

Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers

Adenocarcinoma | Non Small Cell Lung Cancer

Korea, Republic of
Sunshine Lake Pharma Co., Ltd.

Recruiting

Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer

Esophageal Cancer

China
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer

HER2 Positive Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7

United States
Guangdong Association of Clinical Trials
Changhai Hospital; First People's Hospital of Hangzhou; Fudan University; Henan... and other collaborators

Completed

Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer (ISCAN)

Non-small Cell Lung Cancer

China
SCRI Development Innovations, LLC
AstraZeneca; Aventis Pharmaceuticals

Completed

Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer

Head and Neck Cancer

United States
Giselle Sholler
Beat NB Cancer Foundation; K C Pharmaceuticals Inc.; Team Parker for Life; Dell...

Recruiting

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (PEDS-PLAN)

Neuroblastoma

United States, Canada
St. Jude Children's Research Hospital
AstraZeneca; National Institutes of Health (NIH)

Completed

Therapy for Children With Neuroblastoma

Neuroblastoma

United States
National Cancer Institute (NCI)

Terminated

Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer

Mucinous Adenocarcinoma of the Rectum | Signet Ring Adenocarcinoma of the Rectum | Mucinous Adenocarcinoma of the Colon | Signet Ring Adenocarcinoma of the Colon | Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Adenocarcinoma of the Rectum | Adenocarcinoma...

United States
Shenzhen People's Hospital

Unknown

To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma (RCTACSCNSCLC)

NSCLC | EGFR

China
AstraZeneca

Completed

Phase II Iressa & Carbo/Gem in NSCLC

Carcinoma, Non-Small-Cell Lung

Canada
AstraZeneca

Completed

Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study

Breast Cancer

Sweden, Czech Republic, France, Spain, United Kingdom, Hungary, Portugal
Nurex S.r.l.
Purdue University; Università degli Studi di Sassari; Vinmec Healthcare System

Unknown

Triple Antimalarial Combination to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant Parasites (Artesynib)

Plasmodium Falciparum Malaria (Drug Resistant)

Vietnam
Sichuan University
AstraZeneca

Terminated

Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC

Non-small Cell Lung Cancer Metastatic | EGFR Activating Mutation

China
Institute of Cancer Research, United Kingdom
Royal Marsden NHS Foundation Trust

Recruiting

The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial (plasmaMATCH)

Advanced Breast Cancer

United Kingdom
Washington University School of Medicine
United States Department of Defense; Puma Biotechnology, Inc.

Completed

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

Breast Neoplasms

United States, Canada
Intergroupe Francophone de Cancerologie Thoracique
Sanofi; AstraZeneca

Completed

Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV

Carcinoma, Non-Small-Cell Lung

France
Eli Lilly and Company

Active, not recruiting

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) (RELAY)

Metastatic Non-Small Cell Lung Cancer

France, Spain, United States, Italy, Canada, Taiwan, Hong Kong, Japan, Turkey, Korea, Republic of, United Kingdom, Germany, Romania, Greece

Search clinical trials for: Ceritinib (LDK378)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations